Sano Habitrol generic transdermal patch could be marketed by Par Pharmaceuticals.
This article was originally published in The Tan Sheet
Executive Summary
SANO HABITROL GENERIC PATCH COULD BE MARKETED BY PAR if FDA approves the company's ANDA for a version of Ciba's nicotine transdermal patch for smoking cessation, according to a recent prospectus for a proposed public offering. Sano filed its ANDA in January 1995, has "received comments from the FDA...and has responded to those comments," the prospectus states. Miramar, Fla.-based Sano's manufacturing facilities passed an FDA preapproval inspection in July 1996. Ciba's Habitrol patents expire in 2003 and 2006.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning